New US approval for Clovis' Rubraca
admin 9th April 2018 Uncategorised 0Clovis’ PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.
More: New US approval for Clovis' Rubraca
Source: News